|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thandra KC, Barsouk A, Saginala K, Padala
SA, Barsouk A and Rawla P: Epidemiology of non-Hodgkin's lymphoma.
Med Sci (Basel). 9:52021.PubMed/NCBI
|
|
3
|
Pasvolsky O, Rozental A, Raanani P,
Gafter-Gvili A and Gurion R: R-CHOP compared to R-CHOP + X for
newly diagnosed diffuse large B-cell lymphoma: A systematic review
and meta-analysis. Acta Oncol. 60:744–749. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zou L, Song G, Gu S, Kong L, Sun S, Yang L
and Cho WC: Mechanism and treatment of rituximab resistance in
diffuse large bcell lymphoma. Curr Cancer Drug Targets. 19:681–687.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Witlox WJA, Grimm SE, Riemsma R, Armstrong
N, Ryder S, Duffy S, Carrera VH, Posadzki P, Worthy G, Pouwels
XGLV, et al: Lenalidomide with rituximab for previously treated
follicular lymphoma and marginal zone lymphoma: An evidence review
group perspective of a NICE single technology appraisal.
Pharmacoeconomics. 39:171–180. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cho KM, Keam B, Ha H, Kim M, Jung JW, Song
WJ, Kim TM, Jeon YK, Kang HR, Kim DW, et al: Clinical significance
of rituximab infusion-related reaction in diffuse large B-cell
lymphoma patients receiving R-CHOP. Korean J Intern Med.
34:885–893. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jung JW, Kang HR, Lee SH and Cho SH: The
incidence and risk factors of infusion-related reactions to
rituximab for treating B cell malignancies in a single tertiary
hospital. Oncology. 86:127–134. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Paul F and Cartron G: Infusion-related
reactions to rituximab: Frequency, mechanisms and predictors.
Expert Rev Clin Immunol. 15:383–389. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dao KH and Bermas BL: Systemic lupus
erythematosus management in pregnancy. Int J Womens Health.
14:199–211. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taylan A: Rituximab therapy in
pericarditis associated with rheumatoid arthritis. Rheumatol Int.
42:1843–1847. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
D'Arena G, Simeon V, Laurenti L,
Cimminiello M, Innocenti I, Gilio M, Padula A, Vigliotti ML, De
Lorenzo S, Loseto G, et al: Adverse drug reactions after
intravenous rituximab infusion are more common in hematologic
malignancies than in autoimmune disorders and can be predicted by
the combination of few clinical and laboratory parameters: Results
from a retrospective, multicenter study of 374 patients. Leuk
Lymphoma. 58:2633–2641. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Simcock R and Wright J: Beyond performance
status. Clin Oncol (R Coll Radiol). 32:553–561. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu J, Wei J, Jiang X, Yu W, Tong H, Jin
J, Yan S and Xu W: Prognostic effects of clinical parameters,
genetic abnormalities, and subtypes in primary gastric diffuse
large B-cell lymphoma: A cohort analysis of 146 patients. Leuk
Lymphoma. 63:3362–3369. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang YY and Sun RH: Application of PASS in
sample size estimation of non-inferiority, equivalence and
superiority design in clinical trials. Zhonghua Liu Xing Bing Xue
Za Zhi. 37:741–744. 2016.(In Chinese). PubMed/NCBI
|
|
15
|
Gong Y, Luo L, Wang L, Chen J, Chen F, Ma
Y, Xu Z, Sun Y, Luo L, Shi C and Li X: Association of MTHFR and
ABCB1 polymorphisms with MTX-induced mucositis in Chinese
paediatric patients with acute lymphoblastic leukaemia, lymphoma or
osteosarcoma-A retrospective cohort study. J Clin Pharm Ther.
46:1557–1563. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian
Leukaemia and Lymphoma Group and Eastern Cooperative Oncology
Group, ; et al: Recommendations for initial evaluation, staging,
and response assessment of Hodgkin and non-Hodgkin lymphoma: The
Lugano classification. J Clin Oncol. 32:3059–3068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moore JE, Bloom PC, Chu CC, Bruno JE,
Herne CA, Baran AM, Quataert SA, Mosmann TR, Taylor RP, Wallace DS,
et al: Rituximab induced cytokine release with high serum IP-10
(CXCL10) concentrations is associated with infusion reactions. Leuk
Res. 129:1070722023.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fouda GE and Bavbek S: Rituximab
hypersensitivity: From clinical presentation to management. Front
Pharmacol. 11:5728632020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Laudati C, Clark C, Knezevic A, Zhang Z
and Barton-Burke M: Hypersensitivity reactions: Priming practice
change to reduce incidence in first-dose rituximab treatment. Clin
J Oncol Nurs. 22:407–414. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ohata S, Takenaka K, Sugiyama D and
Sugimoto T: Bone marrow infiltration is a distinctive risk factor
for rituximab infusion-related reactions in CD20-positive B-cell
non-Hodgkin lymphoma. Adv Hematol. 2022:36887272022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsutsumi D, Hayama T, Miura K, Uchiike A,
Tsuboi S, Otsuka S, Hatta Y and Kishikawa Y: A novel rituximab
administration protocol to minimize infusion-related adverse
reactions in patients with B-cell lymphoma. Int J Clin Pharm.
44:366–373. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Novelli S, Soto L, Caballero A, Moreno ME,
Lara MJ, Bayo D, Quintas A, Jimeno P, Zamora MI, Bigorra T, et al:
Assessment of confirmed clinical hypersensitivity to rituximab in
patients affected with B-cell neoplasia. Adv Hematol.
2020:42315612020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang BC and Castells MC: Rituximab
hypersensitivity and desensitization: A personalized approach to
treat cancer and connective tissue diseases. Ann Allergy Asthma
Immunol. 123:11–15. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Watanabe A, Shiseki M, Oishi M, Kobayashi
M, Oshima S, Osanai S, Ryuzaki M, Izuka Y, Tanaka N, Ishiyama M, et
al: Successful rituximab treatment in thrombotic thrombocytopenic
purpura patients complicated by other autoimmune disorders: Two
case reports. Intern Med. 60:2859–2862. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Onuora S: Systemic lupus erythematosus:
Rituximab improves SLE disease activity. Nat Rev Rheumatol.
14:622018. View Article : Google Scholar
|
|
26
|
Assadi F, Mazaheri M and Sadeghi-Bodj S:
Randomized controlled trial to compare safety and efficacy of
mycophenolate vs cyclosporine after rituximab in children with
steroid-resistant nephrotic syndrome. Pharmacotherapy. 42:690–696.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Smolen JS, Cohen SB, Tony HP, Scheinberg
M, Kivitz A, Balanescu A, Gomez-Reino J, Cen L, Poetzl J, Shisha T
and Kollins D: Efficacy and safety of Sandoz biosimilar rituximab
for active rheumatoid arthritis: 52-week results from the
randomized controlled ASSIST-RA trial. Rheumatology (Oxford).
60:256–262. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gilaberte RS and Isenberg D: Differences
in the development of adverse infusion reactions to rituximab in
patients with systemic lupus erythematosus, rheumatoid arthritis
and non-Hodgkin's lymphoma-enigma variations. Front Med (Lausanne).
9:8828912022. View Article : Google Scholar : PubMed/NCBI
|
